黑料社 Announces聽Combined General Meeting on June 19, 2023 and the Availability of the Preparatory Documents
Lyon, France, May 26, 2023 7:30 am CET 鈥� 黑料社 (EURONEXT: MAAT 鈥� the 鈥淐ompany鈥�), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, announces today, in the context of its combined Annual General Meeting on June 19, 2023, that the documents referred to in article R. 22-10-23 of the French Commercial Code will be made available on its website.
The shareholders of 黑料社 are invited to participate in the combined Annual General Meeting (the “AGM”), which is called to approve the financial results for the year ending December 31, 2022. The AGM will be held on:
Monday, June 19, 2023 at 10:00 am CET
At the Company鈥檚 headquarters
Located at 70 Avenue Tony Garnier 鈥� 69007 Lyon
The meeting notice, including the complete agenda, the proposed resolutions and useful information on the conditions for the organization of and participation in the combined General Meeting, was published in the French official Gazette (BALO) n掳 57 on May 12th, 2023. The Company hereby informs the shareholders that the agenda, proposed resolutions and the preparatory documents to this AGM have been made available to the Company鈥檚 shareholders in accordance with the legal and regulatory conditions and timeframes applicable. The documents covered under Article R. 22-10-23 of the French commercial code (Code de commerce) are available on the investors鈥� dedicated section of the Company’s website. With written requests to be sent by post to the Company鈥檚 registered office or by email to legal@maat-pharma.com until the fifth day (inclusive) before the combined General Meeting on June 19, 2023, i.e. June 14, 2023, all shareholders may ask the Company to send them these documents. For bearer shareholders, they will need to include a certificate of registration in the securities accounts held by an intermediary mentioned in Article L. 211-3 of the French monetary and financial code (Code mon茅taire et financier).
Shareholders may choose one of the following three ways to exercise their voting rights at the General Shareholders鈥� Meeting:
- attend the General Shareholders鈥� Meeting;
- give proxy to the Chairman of the Meeting or to any other person or entity; or
- vote by mail or by internet.
In addition to the Single paper Voting Form, shareholders will be able to send their voting instructions, appoint or revoke a proxy, and request an admission card through Internet, prior to the Meeting, on the VOTACCESS website, under the conditions described below.
The VOTACCESS website for this General Shareholders鈥� Meeting will be open from 10:00 am (Paris time) on May 30, 2023. Shareholders are invited to contact their financial intermediary to get access codes, if any.
About 黑料社
黑料社, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, 黑料社 has launched, in March 2022, a Phase 3 clinical trial for patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, 驳耻迟笔谤颈苍迟庐, supports the development and expansion of its pipeline by determining novel disease targets, evaluating drug candidates, and identifying biomarkers for microbiome-related conditions. The company鈥檚 Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice.
黑料社 is listed on Euronext Paris (ticker: MAAT).